Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

BACKGROUND: In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. (18)F-labeled 2-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Zukotynski, Katherine, Yap, Jeffrey T, Giobbie-Hurder, Anita, Weber, Jeffrey, Gonzalez, Rene, Gajewski, Thomas F, O’Day, Steven, Kim, Kevin, Hodi, F Stephen, Van den Abbeele, Annick D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331835/
https://www.ncbi.nlm.nih.gov/pubmed/25609545
http://dx.doi.org/10.1186/s40644-014-0030-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331835/
https://www.ncbi.nlm.nih.gov/pubmed/25609545
http://dx.doi.org/10.1186/s40644-014-0030-0

Ejemplares similares